Skip to main content

Volume 3 Supplement 1


Low dose immunoglobulin g for treatment of severe sepsis and septic shock


As an adjunctive treatment in sepsis, patients administered high-dose (0.9g/kg body weight) intravenous immunoglobulin G (IvIgG) did not have a significant survival benefit in a randomized control study (The SBITS study) (1). However, low-dose ivIgG (5g/day 3days) might have some utilities including earlier defervescence and improvements of clinical signs and symptoms (2).


In this retrospective cohort study of patients with severe sepsis and septic shock, we investigated whether low-dose IvIgG was associated with clinically important outcomes including ICU mortality and in-hospital mortality.


This study is a preplanned retrospective analysis of a large database created by Japan SEPTIC DIC study conducted in 41 ICUs. This study investigated associations between sepsis-related coagulopathy, anticoagulation therapies, and clinical outcomes of 3195 adult patients with severe sepsis and septic shock admitted to ICUs in Japan from January 2011 through December 2013. To estimate associations between IvIgG administration and mortalities, multivariable logistic regression modeling and propensity score-based matching were used for analysis with SPSS version 22.


IvIgG was administered in 976 patients (30.5%). Patients administered ivIgG had significantly higher APACHE II scores (24.2 ± 8.8 vs. 22.7 ± 8.6, P < 0.001), and SOFA scores at admission (10.4 ± 4.0 vs. 9.1 ± 4.0, P < 0.001). ICU mortality was higher in patients with IvIgG (23.1% vs. 18.4%, P = 0.003), but IvIgG was not associated with ICU mortality after adjustment for cofactors (OR 1.121, 95%CI 0.879-1.430, P = 0.358). In-hospital mortality in patients receiving IvIgG was similar to those not receiving IvIgG (34.7% vs 31.9% P = 0.118). In a propensity score-matched analysis, both ICU mortality and in-hospital mortality were not different between the groups (22.4% vs. 19.1%, P = 0.088; and 33.7% vs. 31.8%, P = 0.388, respectively).


In our retrospective analysis of a large cohort of severe sepsis and septic shock, administration of low-dose IvIgG as adjunctive therapy for patients with severe sepsis and septic shock was not associated with a reduction in ICU mortality and in-hospital mortality.


  1. Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, et al: Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007, 35 (12): 2693-2701. 10.1097/01.CCM.0000295426.37471.79.

    Article  PubMed  CAS  Google Scholar 

  2. Masaoka T: [Combination therapy of antibiotics and intravenous immunoglobulin]. Nihon Rinsho. 2001, 59 (4): 781-784.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iizuka, Y., Sanui, M., Hayakawa, M. et al. Low dose immunoglobulin g for treatment of severe sepsis and septic shock. ICMx 3 (Suppl 1), A433 (2015).

Download citation

  • Published:

  • DOI: